Evidence Snapshot

Tyrosine-protein kinase JAK3

CHEMBL2148 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:03Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:51 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2148

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase JAK3 as ChEMBL target CHEMBL2148, mapped to UniProt P52333. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Tyrosine-protein kinase JAK3

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2148

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P52333

Tyrosine-protein kinase JAK3

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tyrosine-protein kinase JAK3 matters

As of 2026-09-13

Tyrosine-protein kinase JAK3 is reviewed as Tyrosine-protein kinase JAK3 (UniProt P52333); Tyrosine-protein kinase JAK3 shows approved-linked disease relevance led by rheumatoid arthritis. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 48 approved drugs, 11611 compounds, and 1278 assays, with lead potency reaching pChEMBL 11.0.

Protein context

Tyrosine-protein kinase JAK3

Tyrosine-protein kinase JAK3 Sequence length is 1124 aa.

Review this target as Tyrosine-protein kinase JAK3, mapped to UniProt P52333. Sequence length is 1124 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P52333 Protein

Disease context

rheumatoid arthritis

Tyrosine-protein kinase JAK3 shows approved-linked disease relevance led by rheumatoid arthritis. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include DECERNOTINIB, FILGOTINIB, FILGOTINIB MALEATE.

Start review with rheumatoid arthritis because it currently carries approved-linked support. Linked drugs include DECERNOTINIB, FILGOTINIB, FILGOTINIB MALEATE, RITLECITINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 5 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 48 approved drugs, 11611 compounds, and 1278 assays for this target. The dominant activity type is IC50. CHEMBL3335689 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL3335689 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

48 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tyrosine-protein kinase JAK3 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P52333, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why rheumatoid arthritis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

11611

Total Compounds

1278

Total Assays

Approved Drugs

IC50: 11998.0, KI: 2400.0, EC50: 226.0, KD: 228.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL3335689	11.0	Ki	—
No preferred name CHEMBL3335699	11.0	Ki	—
No preferred name CHEMBL3665184	11.0	IC50	—
No preferred name CHEMBL3665122	11.0	IC50	—
No preferred name CHEMBL3665173	11.0	Ki	—

Approved Drugs

Structure	Compound	First Approval
	MOMELOTINIB CHEMBL1078178	2023
	RITLECITINIB CHEMBL4085457	2023
	DEUCRAVACITINIB CHEMBL4435170	2022
	PACRITINIB CHEMBL2035187	2022
	ABROCITINIB CHEMBL3655081	2021
	FILGOTINIB CHEMBL3301607	2020
	FEDRATINIB CHEMBL1287853	2019
	ZANUBRUTINIB CHEMBL3936761	2019
	UPADACITINIB CHEMBL3622821	2019
	PEFICITINIB CHEMBL3137308	2019
	ENTRECTINIB CHEMBL1983268	2019
	BARICITINIB CHEMBL2105759	2017
	MIDOSTAURIN CHEMBL608533	2017
	PALBOCICLIB CHEMBL189963	2015
	NINTEDANIB CHEMBL502835	2014
	IBRUTINIB CHEMBL1873475	2013
	TOFACITINIB CHEMBL221959	2012
	TOFACITINIB CITRATE CHEMBL2103743	2012
	RUXOLITINIB PHOSPHATE CHEMBL1795071	2011
	RUXOLITINIB CHEMBL1789941	2011
	CRIZOTINIB CHEMBL601719	2011
	DASATINIB CHEMBL5416410	2006
	ERLOTINIB CHEMBL553	2004

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:03Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:51 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2148